Amlexanox vs Tesofensine
Research Verdict
Tesofensine is the stronger research reference for the stated comparison criteria. Tesofensine: Phase 2b RCT (Astrup et al.
Quick Answers
Which is better, Amlexanox or Tesofensine?
Tesofensine is the stronger research reference for the stated comparison criteria. Tesofensine: Phase 2b RCT (Astrup et al.
What is the key difference between Amlexanox and Tesofensine?
Tesofensine is a CNS triple monoamine reuptake inhibitor causing central appetite suppression with cardiovascular side effects (increased heart rate); amlexanox is a peripheral IKKe/TBK1 inhibitor - CNS vs. peripheral mechanism with very different risk profiles.
Evidence Comparison
Tesofensine: Phase 2b RCT (Astrup et al. Lancet 2008, n=203) showing 10.6% weight loss at 0.5 mg over 24 weeks. Amlexanox: pilot study (n=42) with modest metabolic biomarker changes. Tesofensine has meaningfully stronger human efficacy data.
Evidence Context Favoring Amlexanox
Peripheral inflammatory metabolism research via IKKe/TBK1 pathway.
Evidence Context Favoring Tesofensine
Weight loss research requiring human dose-response data, accepting the CNS side-effect profile of triple reuptake inhibition.
Side-by-Side Snapshot
| Evidence grade | Amlexanox: Level C Tesofensine: Level B |
|---|---|
| Research status | Amlexanox: Phase 2 Tesofensine: Phase 3 |
| Primary category | Amlexanox: Weight Loss & Metabolic Tesofensine: Weight Loss & Metabolic |
| Cited studies | Amlexanox: 2 Tesofensine: 2 |